Pherin Pharmaceuticals

Phone Icon (650) 636-7064

New Therapeutics;

Microdose Delivery


Drug Development Expertise for a Better Tomorrow

Pherin Pharmaceuticals is the leader in the development of first-in-class compounds called pherines, administered as a nasal spray in ultra-low dose without the need for systemic exposure. Pherines have excellent safety profile and rapid onset of efficacy demonstrated in clinical trials. We have a diverse product portfolio that increases the probability of commercial success and believe that the therapeutic advantages of our product candidates will result in pherines becoming an important new class of approved pharmaceuticals.



Pherin Pharmaceuticals is a privately held clinical stage drug development company headquartered in Mountain View, California. We focus on the development of proprietary compounds called pherines, for the acute treatment of neuropsychiatric and neuroendocrine conditions.

Pherin Pharmaceuticals is led by a highly experienced senior management team. We have assembled a network of external experts to bring our products through all aspects of development successfully. 



January, 2021 Pherin welcomes Dr. Brad Katz to the Scientific Advisory Board
March 10, 2019 VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)

Contact us for strategic collaborations and licensing opportunities

Mailing Address
Pherin Pharmaceuticals
78 Aquavista
San Francisco, CA  94131

(650) 636-7064